61 Biggest Movers From Yesterday
Gainers
Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
44 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.
Cramer Gives His Opinion On Carlotz, MannKind And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is staying away from Carlotz Inc (NASDAQ: LOTZ). He is done with the used cars for now.
Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18
MannKind Corporation (NASDAQ:MNKD) appreciates the recent efforts of the Centers for Medicare and Medicaid Services (CMS) in conjunction with the Medicare Administration Contractors (MACs) to implement a policy
MannKind Presents Two Posters At American Diabetes Association’s Virtual 81st Scientific Sessions, June 25-29
MannKind Corporation (NASDAQ:MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's
MannKind – United Therapeutics’ Formulated Treprostinil Under FDA Review For Pulmonary Hypertension
MannKind Corporation (NASDAQ:MNKD) and United Therapeutics Corporation (NASDAQ:UTHR) have announced that the FDA has accepted for review the marketing application of Tyvaso DPI…
United Therapeutics Announces FDA Acceptance Of Tyvaso DPI New Drug Application For Priority Review
United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S.
ROCE Insights For MannKind
MannKind (NASDAQ:MNKD) reported Q1 sales of $17.44 million. Earnings fell to a loss of $10.03 million, resulting in a 49.19% decrease from last quarter. MannKind collected $18.44 million in revenue during Q4, but reported earnings showed a $19.74 million loss.
MannKind: Q1 Earnings Insights
Shares of MannKind (NASDAQ:MNKD) rose in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share fell 25.00% over the past year to ($0.05), which missed the estimate of ($0.04).